The Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability
Open Access
- 26 March 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 457
Abstract
Enzalutamide (ENZ), marketed under the brand name Xtandi® as a soft capsule, is an androgen receptor signaling inhibitor drug actively used in clinical settings for treating prostate cancer. However, ENZ’s low solubility and bioavailability significantly hinder the achievement of optimal therapeutic outcomes. In previous studies, a liquid self-nanoemulsifying drug delivery system (L-SNEDDS) containing ENZ was developed among various solubilization technologies. However, powder formulations that included colloidal silica rapidly formed crystal nuclei in aqueous solutions, leading to a significant decrease in dissolution. Consequently, this study evaluated the efficacy of adding a polymer as a recrystallization inhibitor to a solid SNEDDS (S-SNEDDS) to maintain the drug in a stable, amorphous state in aqueous environments. Polymers were selected based on solubility tests, and the S-SNEDDS formulation was successfully produced via spray drying. The optimized S-SNEDDS formulation demonstrated through X-ray diffraction and differential scanning calorimetry data that it significantly reduced drug crystallinity and enhanced its dissolution rate in simulated gastric and intestinal fluid conditions. In an in vivo study, the bioavailability of orally administered formulations was increased compared to the free drug. Our results highlight the effectiveness of solid-SNEDDS formulations in enhancing the bioavailability of ENZ and outline the potential translational directions for oral drug development.Keywords
Funding Information
- National Research Foundation of Korea (2021R1F1A1063123)
This publication has 36 references indexed in Scilit:
- Nanotechnology as a tool to overcome macromolecules delivery issuesColloids and Surfaces B: Biointerfaces, 2022
- Pharmaceutical amorphous solid dispersion: A review of manufacturing strategiesActa Pharmaceutica Sinica B, 2021
- A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologiesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in ratsArchives of Pharmacal Research, 2015
- Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailabilityAsian Journal of Pharmaceutical Sciences, 2014
- Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipineEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage formsDrug Discovery Today, 2008
- Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification systemEuropean Journal of Pharmaceutical Sciences, 2006
- Comparative Bioavailability Study in Dogs of a Self‐Emulsifying Formulation of Progesterone Presented in a Pellet and Liquid form Compared with an Aqueous Suspension of ProgesteroneJournal of Pharmaceutical Sciences, 2004
- Ritonavir–PEG 8000Amorphous Solid Dispersions: In vitro and In vivo EvaluationsJournal of Pharmaceutical Sciences, 2004